Immunovant logo
Immunovant
IMVT | NASDAQ
Chart Builder DCF Calculator
$33.28
-$0.90 (-2.63%)
At close: Nov 16, 2026, 4:00 PM ET
$33.28
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Immunovant Company Profile

Company profile explained

Company Profile

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.

Key Executives

Name Position
Eric Venker Chief Executive Officer & Director
Christopher Van Tuyl Chief Legal Officer & Corporate Secretary
Jay S. Stout Chief Technology Officer
Melanie Gloria Chief Operating Officer
Tiago Girao Chief Financial Officer
Becky Merlina Senior VP & Global Head of Quality
Christine Blodgett Senior Vice President of Human Resources
Frank Torti Executive Chairperson of the Board
Sheetal Patel Senior Vice President of Clinical Development
Yan Zheng Senior Vice President of Biostatistics, Programming & Data Management

Latest SEC Filings

Date Type Title
Oct 30, 2026 4 Filing
Oct 23, 2026 4 Filing
Oct 09, 2026 4 Filing
Oct 09, 2026 4 Filing
Oct 09, 2026 4 Filing
Oct 05, 2026 4 Filing
Sep 25, 2026 4 Filing
Sep 03, 2026 8-K Current Report
Aug 28, 2026 4 Filing
Aug 21, 2026 4 Filing
View All SEC Filings ➞
Immunovant
Immunovant logo
Country United States
IPO Date Jun 21, 2019
Industry Biotechnology
Sector Healthcare
Employees 315
CEO Eric Venker

Contact Details

1000 Park Forty Plaza Durham, New York 27713 United States

Stock Details

Ticker Symbol IMVT
Exchange NASDAQ
Fiscal Year April - March
Reporting Currency USD
CIK Code 0001764013
CUSIP Number 45258J102
ISIN Number US45258J1025
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.